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Abstract
AIDS-related CMV retinitis is a common clinical problem in patients with advanced HIV/AIDS in China and
Southeast Asia. The disease is causing blindness, and current clinical management, commonly characterized by
delayed diagnosis and inadequate treatment, results in poor clinical outcomes: 21% - 36% of eyes with CMV
retinitis are already blind at the time the diagnosis is first established by an ophthalmologist. CMV retinitis also
identifies a group of patients at extraordinary risk of mortality, and the direct or indirect contribution of extra-
ocular CMV disease to AIDS-related morbidity and mortality is currently unmeasured and clinically often
overlooked. The obvious way to improve clinical management of CMV retinitis is to screen all patients with CD4
counts < 100 cells/μL with indirect ophthalmoscopy at the time they first present for care, and to provide systemic
treatment with oral valganciclovir when active CMV retinitis is detected. Treatment of opportunistic infections is an
integral part of HIV management, and, with appropriate training and support, CMV retinitis screening and
treatment can be managed by the HIV clinicians, like all other opportunistic infections. Access to ophthalmologist
has been problematic for HIV patients in China, and although non-ophthalmologists can perform screening,
sophisticated ophthalmological skills are required for the management of retinal detachment and immune
recovery uveitis, the major complications of CMV retinitis. CMV retinitis has been clinically ignored, in part, because
of the perceived complexity and expense of treatment, and this obstacle can be removed by making valganciclovir
affordable and widely available. Valganciclovir is an essential drug for developing successful programs for
management of CMV retinitis in China and throughout SE Asia.
AIDS-related CMV retinitis is a common problem
in China
Cytomegalovirus (CMV), a member of the herpesvirus
family, was a familiar, potentially blinding and lethal
opportunistic infection in high income countries prior to
the introduction of highly active anti-retroviral therapy
(HAART). As the burden of the epidemic shifted to mid-
dle and low income countries, CMV retinitis, the most
common AIDS-related clinical manifestation of CMV
disease, became the “neglected disease of the AIDS pan-
demic” [1]. The current report by Shi, et al [2] brings
important attention to this problem in China: CMV reti-
nitis was found in 16.8% (19/113) of HIV-infected inpati-
ents having CD4 counts < 50 cells/μL (the high-risk
group). The data from Shanghai complement accounts of
CMV retinitis from Beijing [3] and Guangzhou [4], and is
consistent with our personal observation of a similar bur-
den of CMV retinitis during training projects and clinical
work in HIV clinics and infectious disease hospitals
between 2006-2010, in Hubei province and the Autono-
mous Regions of Guangxi and Xinjiang. Although the
authors appropriately suggest that we acquire better epi-
demiologic data, the key point is that there is adequate
evidence that AIDS-related CMV retinitis is a common
clinical problem in China, as in SE Asia [1].
Blindness
The visual consequences of CMV retinitis are disastrous.
In the current report [2], 20.8% (5/24) of eyes with CMV
retinitis were blind at diagnosis. In reports from Thailand
[5,6], 31.2% (92/295) and 31.5% (165/523) of eyes were
blind at diagnosis, and in a report from multiple sites [1],
35.9% (37/103) of eyes with CMV retinitis were blind.
This staggering level of blindness is actually worse than
the simple numbers suggest, for three reasons. First, the
vision loss resulting from CMV retinitis is commonly
severe, with one prior report showing only hand motion
(HM) vision or worse in 33/37 (89.2%) of eyes blinded by
CMV [1]. The World Health Organization (WHO)
defines blindness as < 3/60 visual acuity, which at the
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tance of 10 feet. In reality, blindness includes several dis-
tinct and functionally different groups, and the majority
of patients that meet the WHO definition still retain
enough vision to manage the simple activities of daily liv-
ing (dressing, feeding, navigating to the bathroom, etc.).
But with HM vision or worse, a person requires “sight
substitution,” which in resource-limited settings means
that another person must almost continually provide
assistance; patients with this level of visual disability
struggle to survive.
Second, despite the therapeutic optimism of the current
report [2], CMV infection causes irreversible full-thickness
retinal necrosis, and most vision loss from CMV is perma-
nent (although some improvement may occur with resolu-
tion of adjacent retinal edema and clearing of
inflammatory debris from the vitreous cavity). In contrast,
vision loss from cataract, the most common cause of
blindness, may be cured and vision fully restored.
Third, again unlike cataract, AIDS-related CMV blind-
ness occurs at a young age. Traditionally, epidemiologic
studies for blindness do not even survey the population
less than 40 years of age because blindness before that age
has been so rare. But now, in young patients receiving
effective treatment for HIV/AIDS, there is a progressive
accumulation of unfortunate people who are permanently
and profoundly blind. In an area hard-hit by HIV in north-
ern Thailand, CMV retinitis was found to be the second
most common cause of blindness (following cataract) in a
consecutive series of all patients referred to a University
eye clinic, even though it occurred only in patients
infected with HIV, which represented less than 2% of the
general population [7].
Mortality
The mortality described in this report from Shanghai is
even more striking than the incidence of blindness: 30.4%
(7/23) of patients with CMV retinitis died within 2 weeks.
We observed a similar mortality rate in Yangon, Myanmar
(unpublished abstract, presented at the annual meeting,
Association for Research in Vision and Ophthalmology
(ARVO), May 4, 2010: Outcomes for a 42 patient CMV
Retinitis cohort from the slums of Rangoon. D. Heiden,
N.J.S. London, N. Tun, F. Smithuis.): in a sub-group of
patients diagnosed with active CMV retinitis and followed
30 months: 31.8% (7/22) died, 27.3% (6/22) were con-
firmed alive, and 40.9% (9/22) were lost to follow-up,
including 3 within the first month who almost certainly
died as well.
The relationship between CMV infection and mortality,
a subject of intense interest in the “pre-HAART era” in
the United States and Western Europe, now receives little
attention. Autopsy data is rarely acquired, and it is often
forgotten that disseminated CMV infection was found in
38-59% of patients dying of AIDS [8,9]. In patients who
die of AIDS, the precise reason for a fatal outcome may
be difficult to determine, although the patient with trans-
verse myelitis reported by Shi almost certainly died of
CMV [10]. The evidence linking CMV infection and
excess mortality is complex. Western data has shown
that CMV is a co-factor in AIDS progression [11], and
that CMV viremia [12,13] and retinitis [14] are powerful
predictors of mortality. A report from Cambodia demon-
strated that CMV viremia was associated with a doubling
of mortality [15].
Early diagnosis
Dismal outcomes are inevitable if CMV retinitis is diag-
nosed late. We strongly support Shi’s assertion that retinal
screening should be part of a standard initial evaluation
for all individuals presenting with CD4 counts below 100
cells/μL, and we strongly agree about the importance of
screening asymptomatic patients. This is consistent with
previous evidence and recommendations [16].
CMV retinitis is a clinical diagnosis. The “gold standard”
is examination of the entire retina through a fully dilated
pupil with an indirect ophthalmoscope by an experienced
observer. The characteristic features of CMV retinitis are
easily appreciated. Thus diagnosis can be established
rapidly and at minimal cost in any consultation room or
hospital ward, without need for special testing, eye clinic,
or ophthalmologist. Management of CMV retinitis can in
fact be integrated into the primary care of the patient with
AIDS, just like all other opportunistic infections, and a
recent report from Myanmar describes successful diagnosis
and treatment of CMV retinitis by non-ophthalmologist
HIV clinicians at the primary care level [17]. Innovation is
also taking place in Thailand, where ophthalmologists are
exploring the use of telemedicine to screen for CMV retini-
t i sa tt h ep r i m a r yc a r el e v e l[ 1 8 ] .
Early diagnosis is the most effective way to reduce the
blinding complications of CMV retinitis. The risk of both
retinal detachment and immune recovery uveitis (IRU)
increase as infection advances, and is proportional to the
size of the retinal surface area involved [19,20]. Both of
these complications can be complex and expensive to
treat, and often may have poor outcomes, even with the
best treatments that modern medicine can offer.
Early diagnosis of CMV retinitis depends on patients
having access to care; unfortunately the stigma attached
to HIV in China has commonly excluded patients from
ophthalmological care, particularly surgery [21]. (We
have seen a patient left permanently blind because criti-
cal eye surgery was denied.) The problem of limited
access is compounded by the fact that patients infected
with HIV are often members of marginalized or crimi-
nalized groups (intravenous drug users, commercial sex
workers, and men who have sex with men).
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Systemic treatment regimens for CMV retinitis are com-
plex and burdensome with the single exception of valgan-
ciclovir, a well-absorbed oral pro-drug of ganciclovir, the
“gold standard” for treatment. Valganciclovir gives blood
levels equivalent to intravenous ganciclovir, is equally
effective [22], and has been the foundation for treatment
of CMV retinitis in Western countries for a decade.
Treatment with intravenous ganciclovir is expensive
because it requires hospitalization. With the financial
incentives that are inherent in the current Chinese health
care system, patients may be encouraged down the path of
hospitalization until their money runs out, at which time
treatment may end prematurely and be inadequate.
Outpatient treatment with valganciclovir is far more fea-
sible, but cost is again the issue. In China at this time, the
cost of a typical course of treatment for AIDS-related
CMV retinitis with valganciclovir is approximately equiva-
lent to the cost of purchasing 2 new small cars.
1 Valganci-
clovir is chemically similar to acyclovir, an inexpensive
and widely available medication, so there is little inherent
justification for exorbitant pricing based on the cost of
drug production. This is a sad and unwelcome echo from
a decade ago, when pricing of antiretroviral treatments
kept medication costs beyond the reach of patients dying
of treatable HIV/AIDS [23]. In Thailand, the same issue
was resolved with another opportunistic infection, crypto-
coccal meningitis, where treatment with fluconazole was
out of reach for most patients until generic production
reduced the price by 98%, from $13. USD a day to 30
cents a day, and made fluconazole treatment universally
available [24]. Valganciclovir is an essential drug for the
treatment of CMV retinitis and it must be made affordable
and widely available.
The way forward
CMV retinitis causes blindness and identifies patients at
extraordinary risk of mortality, in China and throughout
SE Asia. All HIV-infected patients with CD4 < 100 cells/
μL, with or without symptoms, should be systematically
screened by retinal examination through a fully dilated
pupil with an indirect ophthalmoscope. This should
occur when the patient first presents for HIV care.
Although it remains conceptually attractive to imagine
that screening arrangements might be organized with
trained ophthalmologists, in practice, after more than a
decade of development of programs for management of
patients with HIV/AIDS in China and SE Asia, there is
still rarely access to ophthalmologists for CMV screening
in a timely fashion. With proper training and support,
retinal screening for CMV retinitis can be performed by
the AIDS clinicians, and treatment can be provided with
oral valganciclovir, with ophthalmologists providing care
for the complications of CMV retinitis, such as retinal
detachment, and IRU. Systemic treatment with valganci-
clovir for patients diagnosed with early disease affords
the best opportunity to reduce blindness and mortality
from this neglected disease.
Endnotes
1One bottle of valganciclovir, containing 60 × 450 mg
tablets, currently costs ~17,000 Renminbi (RMB) or
~2625 USD. A typical anti-CMV treatment regimen
would be 900 mg twice a day for three weeks, followed
by 450 mg twice a day for 9 weeks. This would require
210 pills (3.5 bottles) at a cost of 59,500 RMB. A basic
2011 model of a popular small car in China called
‘Chery QQ3’ can be purchased for <30,000 RMB.
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